Inspire Medical Systems Cuts 2025 Earnings Guidance by 80% Due to Device Launch Delays
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Earnings Guidance Cut: Inspire Medical Systems slashed its 2025 earnings forecast from $2.20-$2.30 per share to $0.40-$0.50, representing an over 80% reduction, indicating weak market demand for its new Inspire V device, which could undermine investor confidence.
- Launch Delays: The launch of Inspire V is facing an “elongated timeframe” due to many treatment centers failing to complete necessary training and contracting, which not only hampers sales progress but also risks losing competitive advantage in a fast-paced market.
- Excess Inventory Issues: The company is grappling with excess inventory, leading to poor demand for Inspire V, a situation that could negatively impact not only short-term sales but also the long-term brand image in the medical device sector.
- Legal Action Risks: Inspire faces class action lawsuits for failing to disclose significant adverse facts related to Inspire V, which may exacerbate investor losses and further damage the company's reputation.
INSP
$97.195+Infinity%1D
Analyst Views on INSP
Wall Street analysts forecast INSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INSP is 115.58 USD with a low forecast of 82.00 USD and a high forecast of 180.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
9 Buy
5 Hold
0 Sell
Moderate Buy
Current: 96.540
Low
82.00
Averages
115.58
High
180.00
Current: 96.540
Low
82.00
Averages
115.58
High
180.00
About INSP
Inspire Medical Systems, Inc. is a medical technology company. The Company is focused on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire therapy is FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. It has developed a novel, closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sells its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ear, nose and throat (ENT) physicians and sleep centers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
